{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:06:47Z","timestamp":1779199607884,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cjcopen.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cjco.2025.08.001","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T23:43:26Z","timestamp":1755128606000},"page":"1621-1628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Factors and Markers for Flecainide Toxicity in Clinical Practice"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-2617","authenticated-orcid":false,"given":"Karim","family":"Khadir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgiana Pintea","family":"Bentea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brahim","family":"Berdaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Castro","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2025.08.001_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1113\/jphysiol.2004.065003","article-title":"State-dependent trapping of flecainide in the cardiac sodium channel","volume":"560","author":"Ramos","year":"2004","journal-title":"J Physiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104443","article-title":"Flecainide: electrophysiological properties, clinical indications, and practical aspects","volume":"148","author":"Paolini","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cjco.2025.08.001_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.65.5.879","article-title":"Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent","volume":"65","author":"Hodges","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.08.001_bib4","series-title":"ClinCalc DrugStats Database, version 2024.01. Medical Expenditure Panel Survey (MEPS) 2013-2021","year":"2025"},{"key":"10.1016\/j.cjco.2025.08.001_bib5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/15563659009038586","article-title":"Clinical course and outcome in class IC antiarrhythmic overdose","volume":"28","author":"K\u00f6ppel","year":"1990","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.cjco.2025.08.001_bib6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.08.001_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2025.08.001_bib8","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0002-9149(02)02867-9","article-title":"Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation","volume":"90","author":"Meinertz","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ahj.2021.08.013","article-title":"Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease","volume":"243","author":"Burnham","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjco.2025.08.001_bib10","first-page":"718","article-title":"Use of antiarrhythmic drugs for rhythm control in patients with atrial fibrillation: a systematic review","volume":"113","author":"Al-Khatib","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib11","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.amjcard.2019.09.008","article-title":"Meta-analysis comparing the relative risk of adverse events for amiodarone versus placebo","volume":"124","author":"Ruzieh","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjco.2025.08.001_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cjco.2025.08.001_bib14","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1016\/j.ijcard.2013.04.047","article-title":"1:1 atrial flutter. Prevalence and clinical characteristics","volume":"168","author":"Brembilla-Perrot","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib15","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/0002-9149(91)90308-8","article-title":"Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial","volume":"68","author":"Akiyama","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40256-021-00483-9","article-title":"Use of flecainide in stable coronary artery disease: an analysis of its safety in both nonobstructive and obstructive coronary artery disease","volume":"21","author":"Ashraf","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cjco.2025.08.001_bib17","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jacep.2022.12.021","article-title":"The feasibility and safety of flecainide use among patients with varying degrees of coronary disease","volume":"9","author":"Kiani","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib18","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/pace.12426","article-title":"Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation","volume":"37","author":"Chung","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00380-014-0534-3","article-title":"Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy","volume":"30","author":"Haruki","year":"2015","journal-title":"Heart Vessels"},{"key":"10.1016\/j.cjco.2025.08.001_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00228-015-1832-0","article-title":"Narrow therapeutic index drugs","volume":"71","author":"Tamargo","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cjco.2025.08.001_bib22","doi-asserted-by":"crossref","first-page":"44A","DOI":"10.1016\/0002-9149(92)91077-H","article-title":"Flecainide acetate in the prevention of paroxysmal atrial fibrillation","volume":"70","author":"Clementy","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/oxfordjournals.eurheartj.a062178","article-title":"Negative inotropic effect of class-I-antiarrhythmic drugs","volume":"8","author":"Hoffmeister","year":"1987","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2025.08.001_bib24","doi-asserted-by":"crossref","first-page":"95B","DOI":"10.1016\/0002-9149(84)90510-1","article-title":"Effects of flecainide on ventricular function","volume":"53","author":"Josephson","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0002-9149(83)80073-3","article-title":"Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818)","volume":"51","author":"Legrand","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0002-9149(82)90423-4","article-title":"Electrophysiologic effects of flecainide acetate in patients with sinus nodal dysfunction","volume":"50","author":"Vik-Mo","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2025.08.001_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/europace\/euq382","article-title":"Twenty-five years in the making: flecainide is safe and effective for atrial fibrillation","volume":"13","author":"Aliot","year":"2011","journal-title":"EP Europace"},{"key":"10.1016\/j.cjco.2025.08.001_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198529010-00001","article-title":"Flecainide","volume":"29","author":"Holmes","year":"1985","journal-title":"Drugs"},{"key":"10.1016\/j.cjco.2025.08.001_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2165\/00044011-199713060-00005","article-title":"Flecainide-induced increase in QRS duration and proarrhythmia during exercise","volume":"13","author":"Bordier","year":"1997","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cjco.2025.08.001_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ipej.2017.12.001","article-title":"Initiation and outcomes with class Ic antiarrhythmic drug therapy","volume":"18","author":"Gao","year":"2018","journal-title":"Indian Pacing Electrophysiol J"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25005207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25005207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:09:54Z","timestamp":1779196194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X25005207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2589790X25005207"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2025.08.001","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors and Markers for Flecainide Toxicity in Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2025.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}